Alerta

REAL-TIME MEAL DETECTION BASED ON SENSOR GLUCOSE AND ESTIMATED PLASMA INSULIN LEVELS

Resumen de: US20260241102A1

0000 Disclosed herein are techniques related to automatic real-time meal detection. In some embodiments, the techniques involve obtaining a plurality of glucose concentration values and a plurality of plasma insulin concentration values. At least one of the plurality of glucose concentration values is obtained within a time range of a determination of a respective plasma insulin concentration value of the plurality of plasma insulin concentration values. The techniques further involve generating an output based on applying a meal detection model to the plurality of glucose concentration values and the plurality of plasma insulin concentration values and determining, based on the output, that a glucose concentration value of the plurality of glucose concentration values corresponds to an ongoing glycemic response to a meal.

SYSTEMS AND METHODS FOR COMPENSATING FOR AGENT ELUTION

Resumen de: US20260240467A1

0000 A method for compensating for a life-lengthening agent for a glucose sensor includes accessing first and second electrochemical impedance spectroscopy (EIS) values of at least one parameter based on first and second EIS procedures performed on EIS signals from a working electrode of the glucose sensor, calculating a change in the at least one parameter between the first and second EIS values, estimating a concentration of the agent based on the change in the at least one parameter, and calculating a model effect in response to the concentration. In a case where the model effect is not greater than the threshold, the method further includes adjusting a sensor glucose value based on the concentration and sensor signals from the working electrode, and displaying the adjusted sensor glucose value.

MUSCLE DIFFERENTIATION-PROMOTING ACTIONS OF ERGOTHIONEINE, ASCORBIC ACID 2-GLUCOSIDE, ASCORBIC ACID, AND COMBINATION THEREOF

Resumen de: US20260242737A1

0000 A culture medium and a culture medium additive which can promote myogenic differentiation. The culture medium and a culture medium additive contain ergothioneine, ascorbic acid 2-glucoside, ascorbic acid, or a combination thereof. A kit, pharmaceutical composition, food, and drink may also promote myogenic differentiation.

COMPOSITION FOR BLOOD GLUCOSE MEASUREMENT AND ELECTROCHEMICAL SENSOR USING SAME

Resumen de: US20260240464A1

0000 A composition for blood glucose measurement includes a copolymer including three types of monomers having a hydrophobic group, a hydrophilic group, and a boronic acid moiety, and a conductive material mixed with the copolymer, thereby enabling volume changes in response to glucose to be converted into electrical signals. An electrochemical sensor for blood glucose measurement includes a working electrode that includes the composition.

INFUSION ELEMENT

Resumen de: US20260241096A1

0000 An infusion element for infusing a substance into a body of a person, comprising: a housing that is suitable for being attached to the skin of said person; an infusion means for infusing the substance into the body of said person, said infusion means being arranged on and/or protruding from the first surface of the housing; at least one sensor for sensing a characteristic of the person, said sensor being arranged on and/or protruding from the first surface of the housing; wherein in use of the infusion element the infusion means is arranged for infusing said substance at a first depth and said sensor is arranged for sensing the characteristic at a second, different depth. A system for regulating the concentration of glucose in the blood of a person comprising such an infusion element.

BLOOD GLUCOSE ASSESSMENT METHOD, USER INTERFACE, AND RELATED APPARATUS

Resumen de: WO2026171056A1

Disclosed in the present application are a blood glucose assessment method, a user interface, and a related apparatus. The method involves two phases: a calibration phase and an assessment phase. In the calibration phase, physical sign data used for reflecting a physical condition of a user, and a blood glucose value can be acquired, and a personalized blood glucose assessment model applicable to the user is obtained on the basis of the physical sign data and the blood glucose value. Then, in the assessment phase, physical sign data of the user is acquired, and a blood glucose result of the user is assessed on the basis of the physical sign data and the blood glucose assessment model, wherein the blood glucose result can be used for indicating a blood glucose condition of the user. In the method, in the calibration phase, the model is determined on the basis of the physical sign data and the blood glucose value, which improves the accuracy of the model. Moreover, in the assessment phase, the blood glucose condition of the user can be assessed without acquiring the blood glucose value, so that the trouble of acquiring the blood glucose value is reduced, and the blood glucose result that is accurate and conforms to an actual condition of the user can be obtained.

METHOD FOR SEARCHING FOR LOST DEVICE, APPLIED TO DIABETES MANAGEMENT SYSTEM

Resumen de: EP4793962A1

0001 The invention discloses a method of locating a lost device in a diabetes management system, the diabetes management system comprises at least one wearable medical device; at least one personal management device and a secondary management device, at least one of the personal management device and the secondary management device is configured to control the wearable medical device, the personal management device and the secondary management device are communicative connection with each other; when either the personal management device or the secondary management device is determined as lost, the other device is used to locate the lost one, thereby enabling the user to retrieve it with ease.

COMPOSITION COMPRISING (A) A DUAL AGENT ACTING AS A 5-HT2A RECEPTOR ANTAGONIST AND CYP2D6 INHIBITOR AND (B) AN NMDA RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF DISEASES INVOLVING GLUCOSE

Resumen de: TW201815387A

Compounds of Formula I: or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, halogenated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of formula I and a compound of Formula II: or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof. Compositions and methods for improving the efficacy of DEX, or providing beneficial pharmacokinetic effects to DEX, comprising co-administering a compound of formula I or SARPO, and a compound of Formula II or DEX to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof.

BODY ATTACHMENT UNIT FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT

Resumen de: KR20200036122A

The present invention relates to a body attachment unit for continuous blood glucose measurement. According to the present invention, a body attachment unit is manufactured in an assembled state in an applicator to minimize extra additional work so that the body attached unit can be attached to a body only by simply operating the applicator. In particular, the body attached unit can be simply and easily used without additional work of connecting an extra transmitter by having a wireless communication chip to communicate with an external terminal. Maintenance of the body attached unit can also be more easily performed. In addition, the body attached unit can be operated by the operation of a user once the body attached unit is attached to the body of the user, and an operation start time point can be adjusted to an appropriate time point as needed. Therefore, the body attached unit can be operated in a more stabilized state to measure blood glucose more accurately.

CELL THERAPY FOR DIABETES IN TRANSPLANT RECIPIENTS

Resumen de: US20260232736A1

Disclosed herein are methods of treating a subject having diabetes with a population of stem cell-derived islet cells and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety. The subject may have received an organ transplant.

METHOD AND APPARATUS FOR ANALYZING BLOOD GLUCOSE CONCENTRATION, ELECTRONIC DEVICE, AND STORAGE MEDIUM

Resumen de: US20260232232A1

A method and apparatus for analyzing a blood glucose concentration, a device, a storage medium, and a computer program product. The method comprises: acquiring intensity sets corresponding to photoplethysmography pulse wave sets for a target object in a target time period, the intensity set comprising an average alternating-current intensity and an average direct-current intensity; performing curve fitting on the intensity sets to obtain a fitting coefficient and a fitting bias; comparing the fitting bias with a bias range corresponding to the target object, and when it is determined that the fitting bias is not within the bias range, adjusting the fitting bias to obtain an adjusted fitting bias; and performing, on the basis of the adjusted fitting bias, curve fitting on the intensity sets to obtain an adjusted fitting coefficient, and taking the adjusted fitting coefficient as the blood glucose concentration of the target object in the target time period.

SYSTEMS, METHODS AND DEVICES FOR BIOPHYSICAL MODELING AND RESPONSE PREDICTION

Resumen de: US20260232230A1

0000 Various systems and methods are disclosed. One or more of the methods disclosed uses machine learning algorithms to predict biophysical responses from biophysical data, such as heart rate monitor data, food logs, or glucose measurements. Biophysical responses may include behavioral responses. Additional systems and methods extract nutritional information from food items by parsing strings containing names of food items.

CANCER MODEL ANIMAL AND METHOD FOR PRODUCING SAME

Resumen de: US20260231913A1

0000 Provided are: a cancer model animal in which a malignant tumor corresponding to a pathological image of human invasive cancer or metastasis has been formed or can be formed, despite the use of transplantation under the skin or into the abdominal cavity; and a method for producing the cancer model animal. One aspect of the present invention is: a cancer model animal in which tumor cells that grow in a culture medium containing L-glucose are transplanted under the skin or into the abdominal cavity; cancer model animal in which tumor cells, such as adenocarcinoma cells, that have been transplanted under the skin or into the abdominal cavity show metastasis; or a cancer model animal in which tumor cells, such as adenocarcinoma cells, that have been transplanted under the skin or into the abdominal cavity show anomaly of function of orthotopic cells.

QUICK SCREENING METHOD FOR ASSESSING DIABETIC FOOT SYNDROME

Resumen de: US20260232202A1

0000 A quick screening method is provided for assessing diabetic foot syndrome for a person. Both feet of the person are positioned onto a testing plate that blocks visible light and permits passage of near infrared (NIR). A multi-spectral camera device is used to simultaneously capture a thermal image and an NIR image of soles of the feet from a side of the testing plate opposite to the feet. The thermal image is aligned with and overlaid onto the NIR image, thereby obtaining an assessment image of the feet. Based on the assessment image, a determination is made regarding whether a temperature difference between a predetermined portion of one foot and a corresponding portion of the other foot exceeds 2.2° C. A potential case of diabetic foot syndrome is reported when the temperature difference exceeds 2.2° C.

SYSTEM FOR REGULATING THE CONCENTRATION OF GLUCOSE IN THE BLOOD OF A PERSON

Resumen de: US20260232892A1

A system for regulating the concentration of glucose in the blood of a person, comprising: a device for selectively supplying insulin and glucagon; at least two infusion sets; at least one sensor for measuring a glucose concentration in the blood of said person; and a controller for controlling said device such that a certain amount of insulin and glucagon is supplied per time unit, wherein said certain amount is chosen in accordance with the measured glucose concentration as prescribed by an insulin injection curve and a glucagon injection curve, wherein said controller is further arranged to determine if glucagon is supplied to said person in a chosen time frame, and wherein the controller is arranged to re-assess and optionally adjust the insulin injection curve based on the determination if glucagon is supplied to said person in said chosen time frame.

PULSEWAVE VELOCITY DETECTION DEVICE

Resumen de: US20260232213A1

0000 A pulsewave velocity detection device provides a photodiode capable of detecting light transmission between 600-700 nm and 880-940 nm and a light emitting diode capable of transmitting the same. An optical isolation spacer separates the photodiode and the LED. A main control chip provides processing of collected pulsewave velocity signal detection by measuring with the photodetector. A microcontroller thereby calculates local metabolic rate, blood flow volume, Hb concentration, oxygen saturation, and corrected blood glucose and correlates a corrected blood glucose value to the calculated local metabolic rate, blood flow volume, Hb concentration, and oxygen saturation. The instant abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

PARENTERAL NUTRITION FORMULATION COMPRISING VITAMIN B12

Resumen de: US20260232717A1

0000 The invention relates to a terminally heat-sterilized multi-chamber container for parenteral nutrition, comprising a first chamber containing a macronutrient formulation and a second chamber comprising a vitamin B12 formulation, wherein the vitamin B12 formulation (a) is essentially free from glucose, amino acids, vitamin B1, ascorbyl palmitate and/or vitamin C; and (b) stably comprises vitamin B12 for at least 6 months at a temperature of from 1° C. to 40° C. and/or for at least 24 months at a temperature of 25° C.

SYSTEM FOR REGULATING THE CONCENTRATION OF GLUCOSE IN THE BLOOD OF A PERSON

Resumen de: US20260232901A1

A system for regulating the concentration of glucose in the blood of a person, comprising: a device for selectively supplying at least one and preferably two substances to said person; at least one and preferably two infusion sets connectable to said device; at least one sensor for measuring a glucose concentration in the blood of said person; a controller for controlling said device such that a certain amount of a said substance is supplied per time unit, wherein said controller is arranged to determine a slope of the measured glucose concentration and if said slope exceeds a first threshold value said controller is arranged to control the device to supply a pre-injection amount of said at least one substance, said pre-injection amount being a percentage of a maximum pre-injection amount, wherein said percentage is dependent on the determined slope.

CHEMICAL ABLATION FOR TREATING VARIOUS DISEASES

Resumen de: EP4789663A2

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

Model predictive control in a closed loop control system for continuous glucose monitoring

Resumen de: US12702755B1

A system which provides closed loop insulin administration is disclosed. A closed loop insulin administration system which bases insulin administration on accurate glucose measurements may improve a patient's quality of life.

METHOD AND ELECTRONIC DEVICE FOR DISPLAYING USER INTERFACE PROVIDING ANALYZED DATA RELATED TO BLOOD GLUCOSE INFORMATION OF USER

Resumen de: WO2026164339A1

A method and an electronic device are provided, the method comprising: acquiring blood glucose information of a user from a continuous blood glucose monitoring device; displaying a user interface including a plurality of objects; changing a specific time indicated by an indicator in response to user interaction with the indicator; displaying a fifth object for inputting an event in response to user interaction with an input component; and storing or transmitting to an external electronic device at least one of a first object, a second object, and a third object in response to user interaction with a fourth object.

METHOD AND ELECTRONIC DEVICE FOR DISPLAYING USER INTERFACE RELATED TO BLOOD GLUCOSE INFORMATION OF USER

Resumen de: WO2026164338A1

Provided are a method and an electronic device, the method comprising: acquiring blood glucose information of a user from a continuous blood glucose monitoring device; displaying a user interface including a plurality of objects; changing a specific time indicated by an indicator in response to user interaction with the indicator; and displaying a fifth object for inputting an event in response to user interaction with an input component.

Systems, devices, and methods for wellness and nutrition monitoring and management using analyte data

Resumen de: AU2026206162A1

A glucose monitoring system, comprising: a glucose sensor comprising a portion configured to be positioned in a body of a user in fluid contact with a bodily fluid to sense glucose in the bodily fluid; and sensor electronics coupled to the glucose sensor, the sensor electronics comprising: one or more processors, memory coupled with the one or more processors, and wireless communication circuitry configured to communicate data indicative of glucose levels based on the sensed glucose in the bodily fluid according to a Bluetooth communication protocol; and a reader device comprising: a display; one or more processors; a transceiver configured to receive the data indicative of the glucose levels; a memory coupled to the one or more processors of the reader device and storing instructions that when executed by the one or more processors of the reader device cause the one or more processors of the reader device to: determine a glucose curve based on the data indicative of the glucose levels, wherein the glucose curve is associated with a glucose response to an event, calculate a numerical score for the event, wherein the numerical score is based in part on an area under the glucose curve and a duration of the glucose response to the event, determine a cumulative score comprising a sum of the numerical scores associated with a plurality of events, and output on the display the cumulative score and a target score. ul u l

INSULIN PATCH PUMP WITH IMPROVED ACTUATION MECHANISM

Resumen de: US20260224809A1

0000 In accordance with one aspect, a medication infusion device is provided that includes a patch pump configured to be removably adhered to a wearer's skin for delivering doses of medication (e.g., insulin) from a cartridge (e.g., a pre-filled cartridge) through a transcutaneous portion. The medication infusion system may include a pumping system configured to advance a plunger in the cartridge to cause medication in the cartridge to be delivered to the patient. The pumping mechanism may be an improved system that reduced errors in medication administration.

ELECTRICALLY-ISOLATED AND MOISTURE-RESISTANT DESIGNS FOR WEARABLE DEVICES

Nº publicación: US20260224136A1 06/08/2026

Solicitante:

DEXCOM INC [US]
VERILY LIFE SCIENCES LLC [US]
DexCom, Inc.
Verily Life Sciences LLC

Resumen de: US20260224136A1

0000 An example continuous glucose monitor includes a printed circuit board (“PCB”) having first and second outer layers and an inner layer; a semiconductor package having a plurality of pins coupled to the first outer layer of the PCB; an electrical contact formed on the second outer layer of the PCB; a trace having a first portion disposed on the first outer layer, a second portion disposed on the inner layer, and a third portion disposed on the second outer layer, the trace having a first end coupled to a first pin of the plurality of pins and a second end coupled to the electrical contact; and an encapsulant disposed around a perimeter of the semiconductor package, the encapsulant covering the plurality of pins, the first portion of the sensor trace, the third portion of the sensor trace, wherein an upper surface of the semiconductor package remains exposed.